MX349886B - Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas. - Google Patents
Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.Info
- Publication number
- MX349886B MX349886B MX2013014372A MX2013014372A MX349886B MX 349886 B MX349886 B MX 349886B MX 2013014372 A MX2013014372 A MX 2013014372A MX 2013014372 A MX2013014372 A MX 2013014372A MX 349886 B MX349886 B MX 349886B
- Authority
- MX
- Mexico
- Prior art keywords
- binding molecules
- psl binding
- pseudomonas psl
- pseudomonas
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a moléculas de unión anti-Ps1 de Pseudomonas y usos de las mismas, en particular en la prevención y el tratamiento de infección por Pseudomonas. Asimismo, la descripción proporciona composiciones y métodos para prevenir y tratar la infección por Pseudomonas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161495460P | 2011-06-10 | 2011-06-10 | |
US201161530461P | 2011-09-02 | 2011-09-02 | |
US201261613317P | 2012-03-20 | 2012-03-20 | |
PCT/US2012/041538 WO2012170807A2 (en) | 2011-06-10 | 2012-06-08 | Anti-pseudomonas psl binding molecules and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014372A MX2013014372A (es) | 2014-08-21 |
MX349886B true MX349886B (es) | 2017-08-17 |
Family
ID=47296761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014372A MX349886B (es) | 2011-06-10 | 2012-06-08 | Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas. |
Country Status (22)
Country | Link |
---|---|
US (4) | US9403901B2 (es) |
EP (2) | EP3385280A1 (es) |
JP (2) | JP6058645B2 (es) |
KR (1) | KR102111171B1 (es) |
CN (1) | CN103974975B (es) |
AU (3) | AU2012267732A1 (es) |
BR (1) | BR112013031485B1 (es) |
CA (1) | CA2838211C (es) |
CY (1) | CY1120557T1 (es) |
DK (1) | DK2718320T3 (es) |
ES (1) | ES2664972T3 (es) |
HK (1) | HK1257190A1 (es) |
HR (1) | HRP20180458T1 (es) |
HU (1) | HUE038509T2 (es) |
LT (1) | LT2718320T (es) |
MX (1) | MX349886B (es) |
PL (1) | PL2718320T3 (es) |
PT (1) | PT2718320T (es) |
RS (1) | RS57024B1 (es) |
RU (2) | RU2708977C2 (es) |
SI (1) | SI2718320T1 (es) |
WO (1) | WO2012170807A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102111171B1 (ko) | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 psl 결합 분자 및 그의 용도 |
KR102184343B1 (ko) * | 2011-11-07 | 2020-11-30 | 메디뮨 엘엘씨 | 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법 |
MX2015005719A (es) * | 2012-11-06 | 2016-01-12 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
US20160115250A1 (en) * | 2013-05-14 | 2016-04-28 | Medlmmune, Llc | Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof |
TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
WO2017095744A1 (en) | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Method for preventing or treating nosocomial pneumonia |
CA3055555A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgf.beta.1-binding immunoglobulins and use thereof |
EA201892525A1 (ru) * | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
CN110475829B (zh) | 2017-04-03 | 2022-09-20 | 富士胶片株式会社 | 油墨组合物及其制造方法、以及图像形成方法 |
GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
US20220153819A1 (en) | 2019-02-12 | 2022-05-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
JP7474393B2 (ja) | 2020-04-22 | 2024-04-25 | センクシア株式会社 | アンカーボルトの施工方法、及びその方法に使用する箱抜き用型枠 |
US20230295279A1 (en) * | 2020-08-07 | 2023-09-21 | Beijing Solobio Genetechnology Co., Ltd. | Antibodies Specifically Recognizing Pseudomonas Psl and Uses Thereof |
WO2024123712A1 (en) * | 2022-12-04 | 2024-06-13 | Genentech, Inc. | Analysis of candidate cytotoxic compositions |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
AU584690B2 (en) * | 1985-03-11 | 1989-06-01 | Teijin Limited | E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
CZ294425B6 (cs) | 1997-04-14 | 2005-01-12 | Micromet Ag | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
JP4368196B2 (ja) | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
US7119172B2 (en) * | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US20030232387A1 (en) | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
US7553936B2 (en) | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
EP2220117A2 (en) * | 2007-11-30 | 2010-08-25 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
EP2248826B1 (en) | 2008-01-10 | 2013-06-12 | Shionogi&Co., Ltd. | Antibody directed against pcrv |
ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
NZ592644A (en) | 2008-11-28 | 2013-09-27 | Abbott Lab | Stable antibody compositions and methods for stabilizing same |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
EP2393515A1 (en) | 2009-02-04 | 2011-12-14 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
US9096659B2 (en) | 2009-03-18 | 2015-08-04 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa |
MX347291B (es) | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
MX2011010634A (es) * | 2009-04-09 | 2012-03-06 | Kenta Biotech Ag | Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa. |
AU2010270979B2 (en) | 2009-06-22 | 2015-04-23 | Medimmune, Llc | Engineered Fc regions for site-specific conjugation |
JP2013515079A (ja) | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ(Pseudomonasaeruginosa)感染症を有する患者のスタフィロコッカス(Staphylococcus)感染症を治療する方法 |
EP2673373B3 (en) | 2011-02-08 | 2021-06-02 | MedImmune, LLC | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
KR102111171B1 (ko) | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 psl 결합 분자 및 그의 용도 |
KR102184343B1 (ko) | 2011-11-07 | 2020-11-30 | 메디뮨 엘엘씨 | 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법 |
EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
KR102272744B1 (ko) | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
MX2015005719A (es) | 2012-11-06 | 2016-01-12 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
PL2917360T3 (pl) | 2012-11-06 | 2020-06-29 | Medimmune, Llc | Przeciwciała dla determinant powierzchniowych S. aureus |
US20160115250A1 (en) | 2013-05-14 | 2016-04-28 | Medlmmune, Llc | Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof |
EP3139950A4 (en) | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
WO2017095744A1 (en) | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Method for preventing or treating nosocomial pneumonia |
EA201892525A1 (ru) | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
JP6988094B2 (ja) | 2017-01-27 | 2022-01-05 | 富士フイルムビジネスイノベーション株式会社 | ポリイミド前駆体組成物、及びポリイミド成形体の製造方法 |
-
2012
- 2012-06-08 KR KR1020137035124A patent/KR102111171B1/ko active IP Right Grant
- 2012-06-08 RU RU2018102606A patent/RU2708977C2/ru active
- 2012-06-08 LT LTEP12796646.3T patent/LT2718320T/lt unknown
- 2012-06-08 MX MX2013014372A patent/MX349886B/es active IP Right Grant
- 2012-06-08 RU RU2014100111/10A patent/RU2014100111A/ru not_active Application Discontinuation
- 2012-06-08 RS RS20180333A patent/RS57024B1/sr unknown
- 2012-06-08 ES ES12796646T patent/ES2664972T3/es active Active
- 2012-06-08 PL PL12796646T patent/PL2718320T3/pl unknown
- 2012-06-08 PT PT127966463T patent/PT2718320T/pt unknown
- 2012-06-08 CA CA2838211A patent/CA2838211C/en active Active
- 2012-06-08 CN CN201280028257.7A patent/CN103974975B/zh active Active
- 2012-06-08 SI SI201231259T patent/SI2718320T1/en unknown
- 2012-06-08 JP JP2014514881A patent/JP6058645B2/ja active Active
- 2012-06-08 US US14/125,073 patent/US9403901B2/en active Active
- 2012-06-08 HU HUE12796646A patent/HUE038509T2/hu unknown
- 2012-06-08 WO PCT/US2012/041538 patent/WO2012170807A2/en active Application Filing
- 2012-06-08 BR BR112013031485-0A patent/BR112013031485B1/pt active IP Right Grant
- 2012-06-08 EP EP17205254.0A patent/EP3385280A1/en active Pending
- 2012-06-08 EP EP12796646.3A patent/EP2718320B1/en active Active
- 2012-06-08 DK DK12796646.3T patent/DK2718320T3/en active
- 2012-06-08 AU AU2012267732A patent/AU2012267732A1/en not_active Abandoned
-
2016
- 2016-06-24 US US15/192,072 patent/US10370436B2/en active Active
- 2016-12-07 JP JP2016237276A patent/JP6420813B2/ja active Active
-
2017
- 2017-06-29 AU AU2017204447A patent/AU2017204447B2/en active Active
-
2018
- 2018-03-19 HR HRP20180458TT patent/HRP20180458T1/hr unknown
- 2018-03-20 CY CY20181100322T patent/CY1120557T1/el unknown
- 2018-12-18 HK HK18116167.3A patent/HK1257190A1/zh unknown
-
2019
- 2019-05-01 US US16/400,818 patent/US10844114B2/en active Active
- 2019-10-28 AU AU2019257355A patent/AU2019257355A1/en not_active Abandoned
-
2020
- 2020-10-19 US US17/073,879 patent/US20210130442A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX349886B (es) | Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas. | |
WO2013070615A8 (en) | Combination therapies using anti- pseudomonas psl and pcrv binding molecules | |
EA201291031A1 (ru) | Способ лечения ожирения с применением антиоксидантных модуляторов воспаления | |
MX2013012165A (es) | Composicion y metodo para mejorar una respuesta inmune. | |
MX2018009553A (es) | Metodos de seleccion. | |
IN2012DN03883A (es) | ||
MX349827B (es) | Compuestos que contienen nitrogeno y su uso. | |
TN2013000310A1 (en) | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections | |
MX2015007556A (es) | Derivados de manosa para tratar infecciones bacterianas. | |
IN2015DN02634A (es) | ||
PH12017500864A1 (en) | Anti-notch1 antibodies | |
MX2012010671A (es) | Compuestos antiinfecciosos. | |
MX354988B (es) | Formulaciones de anticuerpo y metodos. | |
WO2011129936A3 (en) | Compositions and methods for the prevention and treatment of cancer | |
MX2012013875A (es) | Anticuerpos de union sparc en sangre periferica y usos de los mismos. | |
WO2012017321A3 (en) | Treatment for dyslipidemia | |
UA115305C2 (uk) | Композиції hyr1-похідних і способи лікування ними | |
IN2014DN08385A (es) | ||
WO2013037943A8 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
IN2014DN00254A (es) | ||
EP2576536A4 (en) | INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE | |
WO2013166282A3 (en) | Methods and compositions for treating bacterial infection | |
WO2013106460A3 (en) | Compositions and methods for treating malignant astrocytomas | |
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
EP2597949A4 (en) | SUBMIKROMETERZUSAMMENSETZUNGEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |